Ben brings both biopharma expertise and diverse experience. For the past five and a half years, he was a senior manager in PwC’s Health Research Institute. He developed reports on various policy issues and business trends, particularly in the pharma and medtech sectors, provided research for clients and spoke at industry events. Previously, he was a journalist with Pharmaceutical Executive; Medical Marketing & Media, PRWeek and Direct Marketing News; and Ad-Fax Media. During his college days, he taught English in China.
He lives in Orlando, Fla. Outside of work, Ben enjoys playing guitar, welcomes your recommendations for great novels and avidly pursues hiking, biking and other outdoor activities.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ben Comer
Despite a reprieve last summer from the Trump administration’s proposed drug price rebate rule, speakers at the 25th annual Pharmacy Benefit Manager Institute kept the focus on price transparency and talked up new ways to manage drug costs for patients in need of treatment.
DTC spending had shown an uptick in 2020 compared with 2019. Many advertisers are not, however, providing clear drug pricing information in their TV spots, despite some voluntary commitments to do so.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.
Merck and Bristol-Myers Squibb's market-dominating checkpoint inhibitors are competing to find the next combination therapy to treat more cancer patients, in more types of cancers. Recent failures and new regulatory pressure, however, may have a cooling effect, even as researchers come full circle with PD-l/PD-L1 and CTL-4 combinations. The race is also on to pull new combinations from emerging cell therapy and precision oncology drug candidates.
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.